

REMARKS

Claims 88, 89, 94-101, 106 and 107 are currently pending. Claims 88, 89, 95, 97, 98, 101, 106 and 107 have been amended. Claims 90-93, 102-105 and 108-111 have been canceled without prejudice to the prosecution of their subject matter in other patent applications. The amended claims are supported by the specification and the claims as originally filed. In particular, the amendments are supported by the specification at, for example, abstract; page 2, lines 13-21; page 16, line 18 to page 25, line 18; and original claims 1, 13 and 21. No new matter has been added.

Claims 88-111 are rejected under 35 U.S.C. § 112, ¶ 1, for lack of written description for “a sequence at least 90% identical to one of SEQ ID NOS: 1 to 8 or has an end terminal deletion of one of SEQ ID NOS: 1 to 8 ... wherein each peptide in the panel retains the ability to be recognized by T cells of a T cell population which recognize a peptide having a corresponding exact sequence of SEQ ID NOS: 1 to 8....”

In order to expedite prosecution of the application, Applicants have amended the pending claims to delete this or similar recitation from the pending claims without prejudice to the prosecution of the cancelled subject matter in other patent applications. In view of the claim amendments, the pending claims are adequately described in the application as filed. Accordingly, Applicants respectfully request withdrawal of the forgoing rejection.

CONCLUSION

Entry of the foregoing amendments and remarks into the file of the above-identified application is respectfully requested. Withdrawal of the sole rejection is also requested.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or refund any overpayments to Deposit Account No. 02-4377.

Respectfully submitted,



Ling Zhong
Patent Office Reg. No. 48,290

Lisa B. Kole
Patent Office Reg. No. 35,225

Attorney for Applicants
BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112--4498
(212) 408-2500